Malabsorption-associated warfarin resistance

American Journal of Health-System Pharmacy

Volumn 66, Issue 17, 2009, Pages 1548-1553

  Sabol, Brian J ^a,d   Basa, Ramon R ^a   Wilkins, Charles E ^b,c  

^a St Claire Hospital   (United States)

^b SEHC

^c Northeast Ohio Medical University   (United States)

^d ST ELIZABETH HEALTH CENTER   (United States)

Author keywords

Absorption; Albuterol; Anticoagulants; Aspirin; Atorvastatin calcium; Diazepam; Dosage; Fluticasone; International normalized ratio; Metoprolol tartrate; Salmeterol; Venous thrombosis; Warfarin sodium

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; DIAZEPAM; FLUTICASONE; HEPARIN; METOPROLOL TARTRATE; PANTOPRAZOLE; SALBUTAMOL; SALMETEROL; WARFARIN;

ADULT; ANAMNESIS; ARTICLE; ASTHMA; BLEEDING; CASE REPORT; DEEP VEIN THROMBOSIS; DIAPHORESIS; DYSPNEA; GENETIC ANALYSIS; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALABSORPTION; MALE; NAUSEA; PRIORITY JOURNAL; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VENA CAVA FILTER; VOMITING;

EID: 69749121435     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080477     Document Type: Article

References (31)

1. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133(suppl 6):160S-198S. (Pubitemid 351892962)
2. Porter RS, Sawyer WT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics; 1992:31-1-46.
3. Gardemann A, Lohre J, Katz N et al. The 4G4G genotype of the pasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost. 1999; 82:1121-1126 (Pubitemid 29419730)
4. Seguí R, Estellés A, Mira Y et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000; 111:122-128 (Pubitemid 30832441)
5. Lefrere JJ, Guyon F, Horellou MH et al. Selective malabsorption of anticoagulants. JAMA. 1986; 256:595-596 Letter.
6. Talstad I, Gamst ON. Warfarin resistance due to malabsorption. J Intern Med. 1994; 236:465-467
7. Lara LF, Delgado LL, Frazee LA et al. A subtherapeutic international normalized ratio despite increasing doses of warfarin: could this be malabsorption? Am J Med Sci. 2000; 320:214-218
8. Gellatly RM. Intravenous warfarin as an alternative for anticoagulation. Pharmacotherapy. 2007; 27:933-935
9. O'Reilly RA, Aggeler PM, Hoag MS et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Engl J Med. 1964; 271:809-815
10. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann N Y Acad Sci. 1968; 151:913-931
11. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med. 1970; 282:1448-1451
12. Alving BM, Strickler MP, Knight RD et al. Hereditary warfarin resistance: investigation of a rare phenomenon. Arch Intern Med. 1985; 145:499-501.
13. Reider MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352:2285-2293
14. Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy. 1996; 16:1009-1017
15. Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med. 1983; 308:1229-30. Letter.
16. Aithal GP, Day CP, Kesteven PJ et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353:717-719
17. Loebstein R, Yonath H, Peleg D et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther. 2001; 70:159-164
18. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001; 40:587-603. (Pubitemid 32758581)
19. Wagner JG, Welling PG, Lee KP et al. In vivo and in vitro availability of commercial warfarin tablets. J Pharm Sci. 1971; 60:666-677
20. Breckenridge AM, Orme M, Wesseling H et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharm Ther. 1974; 15:424-30.
21. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974; 16:348-354
22. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulants. J Clin Invest. 1963; 42:1542-1551
23. Breckenridge AM, Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther. 1973; 14:955-961
24. Fremont R, Jagendorf B. Clinical observations on use of warfarin (Coumadin) sodium, a new anticoagulant. JAMA. 1957; 165:1382-1388
25. Harrison L, Johnston M, Massicotte MP et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997; 126:133-6. (Pubitemid 27058587)
26. Crowther MA, Ginsberg JB, Kearon C et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999; 159:46-48
27. Lehman ME, Kolb KW, Barnhart GR et al. Warfarin absorption in a patient with short-bowel syndrome. Clin Pharm. 1985; 4:325-326
28. Lutomski DM, LaFrance RJ, Bower RH et al. Warfarin absorption after massive small bowel resection. Am J Gastroenterol. 1985; 80:99-102. (Pubitemid 15137201)
29. Kearns PJ Jr, O'Reilly RA. Bioavailability of warfarin in a patient with severe short bowel syndrome. J Patenter Enteral Nutr. 1986; 10:100-101
30. Owens JP, Mirtallo JM, Murphy CC. Oral anticoagulation in patients with short-bowel syndrome. DICP. 1990; 24:585-589 (Pubitemid 20189002)
31. Brophy DF, Ford SL, Crouch MA. Warfarin resistance in a patient with short bowel syndrome. Pharmacotherapy. 1998; 18:646-649